(NASDAQ: ARCT) Arcturus Therapeutics Holdings's forecast annual revenue growth rate of 54.74% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Arcturus Therapeutics Holdings's revenue in 2026 is $82,031,000.On average, 13 Wall Street analysts forecast ARCT's revenue for 2026 to be $2,339,389,117, with the lowest ARCT revenue forecast at $845,671,572, and the highest ARCT revenue forecast at $5,190,052,399. On average, 10 Wall Street analysts forecast ARCT's revenue for 2027 to be $4,519,552,202, with the lowest ARCT revenue forecast at $1,392,730,381, and the highest ARCT revenue forecast at $16,937,306,817.
In 2028, ARCT is forecast to generate $9,315,945,095 in revenue, with the lowest revenue forecast at $2,109,474,912 and the highest revenue forecast at $28,304,544,802.